Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Post by cpacon Dec 27, 2019 8:55am
273 Views
Post# 30493130

Is this the prelude to a buyout?

Is this the prelude to a buyout?Call me a conspiracy theorist, but I feel like sometimes for greatly undervalued companies, it slips out from someone that company X is in talks to be acquired by company Y, it also slips that management would refuse to entertain an offer below $XXX million.  Frenzied trading pushes the price closer to that value so that when the buyout is announced, it doesn't look so eye-watering to the shareholders of the acquiring company... i.e. we acquired Oncolytics at a 87% premium to the latest share price (rather than "we paid 10x the share price to acquire Oncolytics")  

Many on this board have long believed in ONC's potential to change the cancer landscape, but this trading lately feels like something more than traders finally 'getting religion' on ONC's long term potential!
Bullboard Posts